iTeos Therapeutics Inc (ITOS) Actualités

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate...

Form 4 - Statement of changes in beneficial ownership of securities

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate...

Form 8-K - Current report

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq:...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab...

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq:...

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq:...